Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05734690 · ClinicalTrials.gov registry record · Phase 4
COPILOT-HF: Cooperative Program for ImpLementation of Optimal Therapy in Heart Failure
A Phase 4 study of Heart Failure, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 503
- Enrollment target
- 1
- Study location
NCT05734690 is a Phase 4 study of Heart Failure that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 503 participants, below the 2,048-participant average among 397 other Heart Failure trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05734690, a Phase 4 study of Heart Failure, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 503 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a randomized, open-label, initiative within the Mass General Brigham healthcare system testing two remote care strategies for optimizing the prescription of guideline-directed medical therapies in patients with heart failure, regardless of left ventricular ejection fraction (LVEF).
Conditions Studied
Interventions
- BEHAVIORAL Education-First
- DRUG SGLT2i, beta blocker, ARNI, MRA, MTD
Study Locations (1)
Massachusetts
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 503 participants |
| Start Date | 2023-05-05 |
| Est. Completion | 2025-06-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05734690
The ClinicalTrials.gov registry entry for NCT05734690 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 503 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,048-participant average among 397 other Heart Failure trials with a reported enrollment target (75% lower). The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Heart Failure appearing as the primary indexed condition, and to 2 interventions - of which Education-First is the first listed.
NCT05734690 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05734690 about?
NCT05734690 is a clinical study titled "COPILOT-HF: Cooperative Program for ImpLementation of Optimal Therapy in Heart Failure". This is a randomized, open-label, initiative within the Mass General Brigham healthcare system testing two remote care strategies for optimizing the prescription of guideline-directed medical therapies in patients with heart failure, regardless of left ventricular ejection fraction (LVEF).
What is the current status of trial NCT05734690?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 503 participants. The study started on 2023-05-05. Estimated completion is 2025-06-09.
What conditions does trial NCT05734690 study?
This clinical trial studies the following conditions: Heart Failure.
What interventions are being tested in trial NCT05734690?
The interventions under investigation include: Education-First (BEHAVIORAL), SGLT2i, beta blocker, ARNI, MRA, MTD (DRUG).
Who is sponsoring clinical trial NCT05734690?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05734690 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Gator SCALES-WHF: SubCutaneous Administration of Lasix to Eliminate Symptoms of Worsening Heart Failure
RECRUITING · Phase 4
-
Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure
RECRUITING · Phase 4
-
Treatment Of Atrial Fibrillation In Preserved Cardiac Function Heart Failure
RECRUITING · Phase 4
-
The STOP-MED CTRCD Trial
RECRUITING · Phase 4
-
IRONICA: IRON Repletion In Heart Failure - A Comparison of Oral and IV Approaches
RECRUITING · Phase 4
-
Efficacy Of Sodium Glucose Transporter Inhibitor (SGLT2I) In Adult Patients With Congenital Heart Disease
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.